Research Reports

Every report we've published, newest first.

EVTV

EVTV: The Electric Vehicle Stock That Broke Bad and Went Full AI — Tape Read

Mar 18, 2026

EVTV's 46% rip on 8.3M volume tells the story of a desperation pivot gone right, but dilution demons still lurk in the shadows.

Read →
ARTL

ARTL Pops 33% on Glaucoma Study Deal, But Don't Ignore the Warning Signs

Mar 18, 2026

ARTL exploded 33% on glaucoma study news with 72x float volume, but the cash burn and dilution risks make this more squeeze than substance.

Read →
VNRX

VNRX Pops 39% on "World-First" Liquid Biopsy Breakthrough Amid Delisting Risks

Mar 18, 2026

VNRX explodes 39% on breakthrough liquid biopsy claims, but massive volume and delisting pressures create a complex risk-reward setup.

Read →
LBGJ

LBGJ: The Anatomy of a 138% Pre-Market Pump — And Why It's Already Unwinding

Mar 18, 2026

LBGJ rockets 138% in pre-market but immediately begins fading from highs, exposing the mechanical nature of the move and underlying dilution risks.

Read →
AIM

AIM ImmunoTech (AIM) Explodes 110% Pre-Market After Japan Patent Win Triggers Fresh Catalyst

Mar 18, 2026

AIM explodes 110% pre-market after securing final Japanese patent approval for Ampligen cancer combination therapy, but dilution risks loom from recent rights offering.

Read →
BIAF

BIAF's Wild March Ride: The Rise, the Hype, and the Reality Check

Mar 17, 2026

bioAffinity Technologies exploded 122% on March 13 earnings, then gave back gains as investors parsed the dilution-heavy reality behind the revenue surge.

Read →
UCAR

UCAR Explodes 67% Pre-Market: Thailand Truck Deal Sparks Skepticism and Opportunity

Mar 17, 2026

UCAR explodes 67% pre-market on Thailand battery-truck news, but the skeptic's math reveals dilution risks that bulls are ignoring in this micro-cap momentum play.

Read →
LNAI

LNAI: When The Float Breaks — Anatomy of a 160% Pre-Market Spike Gone Wrong

Mar 17, 2026

LNAI exploded 160% pre-market Monday on classic squeeze mechanics, but this dying biotech's final spike before potential delisting represents everything dangerous about small-cap trading.

Read →
WNW

WNW Stock Rockets 570% on AI Initiative, But Dilution Risk Looms Large

Mar 16, 2026

Meiwu Technology's shares exploded from $1.80 to $13.52 after announcing an AI-powered skincare R&D program, but recent dilution and pending shelf offerings cloud the momentum play.

Read →
ABCD

ABCD Pre-Market Momentum: The Filing Nobody's Talking About

Mar 14, 2026

ABCD ripped 18% pre-market on volume that doesn't match anything in the last 30 days. No PR. No earnings. So what moved it?

Read →
EFGH

EFGH Postmortem: How a 424B5 Filing Turned a 40% Runner Into a Trap

Mar 13, 2026

EFGH ran 40% in the first hour yesterday. By close, it was red. Here's what the filing told you at 7 AM that most people didn't read until it was too late.

Read →
IJKL

IJKL: FDA Catalyst, Tight Float, and a Setup That Actually Looks Interesting

Mar 12, 2026

Most small-cap FDA plays are lottery tickets. IJKL might actually have the structure to hold a move — if you understand the float dynamics.

Read →